Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Shares Issued (2016 - 2025)

Ocular Therapeutix (OCUL) has 13 years of Shares Issued data on record, last reported at $538.9 million in Q4 2025.

  • For Q4 2025, Shares Issued rose 76.33% year-over-year to $538.9 million; the TTM value through Dec 2025 reached $539.6 million, up 70.56%, while the annual FY2025 figure was $539.6 million, 70.56% up from the prior year.
  • Shares Issued reached $538.9 million in Q4 2025 per OCUL's latest filing, up from -$6.5 million in the prior quarter.
  • Across five years, Shares Issued topped out at $538.9 million in Q4 2025 and bottomed at -$305.6 million in Q3 2024.
  • Average Shares Issued over 5 years is $42.9 million, with a median of $324000.0 recorded in 2023.
  • The widest YoY moves for Shares Issued: up 99121.1% in 2024, down 244580.8% in 2024.
  • A 5-year view of Shares Issued shows it stood at -$1.4 million in 2021, then surged by 102.24% to $32000.0 in 2022, then skyrocketed by 862.5% to $308000.0 in 2023, then soared by 99121.1% to $305.6 million in 2024, then soared by 76.33% to $538.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Issued were $538.9 million in Q4 2025, -$6.5 million in Q3 2025, and $3.1 million in Q2 2025.